US healthcare employees receiving extra vaccine doses throughout the Omicron interval (December 2021 to April 2022) had a forty five% decrease threat of getting signs 6 weeks after COVID-19 an infection, in keeping with a research immediately in Open Discussion board Infectious Illnesses.
The research outcomes got here from self-reported symptom questionnaires accomplished 6 weeks after the onset of signs, and was a sub-analysis of knowledge collected throughout the Stopping Rising Infections by Vaccine Effectiveness Testing Undertaking (Undertaking PREVENT).
In whole, the researchers enrolled 2,478 contributors, of whom 1,422 (57%) had COVID-19. All contributors have been absolutely vaccinated with two doses of COVID-19 vaccine, and 66.3% had obtained a 3rd, booster dose. All contributors reported COVID-19–like signs inside 14 days of a qualifying check.
The prevalence of signs at 6 weeks was 26% (373) in these with COVID-19 and 18% (195) in these with out COVID-19. SARS-CoV-2–optimistic contributors had both fever or cough as an preliminary symptom in 71.9% of instances.
Decrease odds of signs with latest booster
Amongst contributors who had COVID-19, those that had obtained an extra COVID-19 vaccine dose had a decrease prevalence of any signs than those that had not at 6 weeks post-infection (adjusted odds ratio [aOR]0.55; 95% confidence interval [CI]0.43 to 0.70).
If the third vaccine dose was administered 16 weeks or much less earlier than an infection, healthcare suppliers had decrease odds of reporting respiratory signs (aOR, 0.69; 95% CI, 0.46 to 0.99), psychiatric signs (aOR, 0.68; 95% CI, 0.47 to 0.99), or any symptom (aOR, 0.68; 95% CI, 0.53 to 0.87) than those that obtained the dose greater than 16 weeks earlier.
COVID-19 vaccination may result in fewer 6-week signs amongst individuals with symptomatic an infection due to its impact in attenuating the severity of acute sickness.
“COVID-19 vaccination may result in fewer 6-week signs amongst individuals with symptomatic an infection due to its impact in attenuating the severity of acute sickness,” the authors concluded.
